Disc Medicine (IRON) – Investment Analysts’ Recent Ratings Changes

Disc Medicine (NASDAQ: IRON) has recently received a number of price target changes and ratings updates:

• 4/8/2024 – Disc Medicine had its price target raised by analysts at Stifel Nicolaus from $71.00 to $73.00. They now have a “buy” rating on the stock.
• 4/2/2024 – Disc Medicine had its price target lowered by analysts at BMO Capital Markets from $80.00 to $50.00. They now have an “outperform” rating on the stock.
• 4/2/2024 – Disc Medicine had its price target lowered by analysts at Morgan Stanley from $75.00 to $40.00. They now have an “equal weight” rating on the stock.
• 4/2/2024 – Disc Medicine had its price target lowered by analysts at Stifel Nicolaus from $104.00 to $71.00. They now have a “buy” rating on the stock.
• 4/1/2024 – Disc Medicine had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $43.00 price target on the stock, down previously from $84.00.
• 4/1/2024 – Disc Medicine had its “outperform” rating reaffirmed by analysts at Raymond James. They now have a $40.00 price target on the stock, down previously from $75.00.
• 4/1/2024 – Disc Medicine had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
• 3/22/2024 – Disc Medicine had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
• 3/21/2024 – Disc Medicine had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $84.00 price target on the stock, up previously from $79.00.
• 2/29/2024 – Disc Medicine had its price target raised by analysts at BMO Capital Markets from $70.00 to $80.00. They now have an “outperform” rating on the stock.

Disc Medicine Trading Down 4.1 %

IRON stock traded down $1.31 during midday trading on Monday, hitting $30.52. The company’s stock had a trading volume of 387,330 shares, compared to its average volume of 425,234. The company has a market cap of $736.75 million, a PE ratio of -8.74 and a beta of 0.18. The firm’s 50-day moving average is $58.73 and its 200-day moving average is $55.98. Disc Medicine, Inc. has a 12 month low of $21.70 and a 12 month high of $77.60.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, March 21st. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.22). Analysts expect that Disc Medicine, Inc. will post -4.44 earnings per share for the current year.

Insider Buying and Selling at Disc Medicine

In related news, major shareholder Venture Fund X. L.P. Atlas sold 47,500 shares of the firm’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $67.65, for a total value of $3,213,375.00. Following the transaction, the insider now owns 1,402,186 shares of the company’s stock, valued at $94,857,882.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Disc Medicine news, Director Kevin Bitterman sold 102,500 shares of the company’s stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $67.65, for a total value of $6,934,125.00. Following the completion of the sale, the director now owns 198,326 shares in the company, valued at $13,416,753.90. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Venture Fund X. L.P. Atlas sold 47,500 shares of Disc Medicine stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $67.65, for a total value of $3,213,375.00. Following the transaction, the insider now directly owns 1,402,186 shares in the company, valued at $94,857,882.90. The disclosure for this sale can be found here. 4.71% of the stock is owned by corporate insiders.

Institutional Trading of Disc Medicine

Institutional investors and hedge funds have recently modified their holdings of the company. Strs Ohio purchased a new stake in Disc Medicine in the 3rd quarter worth $28,000. Ameritas Investment Partners Inc. bought a new stake in shares of Disc Medicine in the second quarter worth about $28,000. Steward Partners Investment Advisory LLC lifted its position in shares of Disc Medicine by 50.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 600 shares of the company’s stock worth $35,000 after buying an additional 200 shares in the last quarter. Bank of America Corp DE grew its holdings in Disc Medicine by 134,000.0% during the 1st quarter. Bank of America Corp DE now owns 2,682 shares of the company’s stock valued at $57,000 after buying an additional 2,680 shares in the last quarter. Finally, AJOVista LLC purchased a new position in Disc Medicine during the 4th quarter valued at approximately $63,000. 83.70% of the stock is currently owned by institutional investors.

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.